- Home
- BEAM vs ZD Comparison
BEAM vs ZD Comparison
Compare BEAM & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | ZD |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.9B |
| IPO Year | 2019 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BEAM | ZD |
|---|---|---|
| Price | $23.35 | $59.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | ★ $50.75 | $39.71 |
| AVG Volume (30 Days) | ★ 1.8M | 479.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ 17.49 |
| Revenue | $24,000.00 | ★ $1,364,028,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | $2.16 |
| P/E Ratio | ★ N/A | $3.39 |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $20.23 | $22.45 |
| 52 Week High | $38.26 | $58.06 |
Technical Indicators
Market Signals| Indicator | BEAM | ZD |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 69.76 |
| Support Level | $21.63 | $50.59 |
| Resistance Level | $28.96 | N/A |
| Average True Range (ATR) | 1.31 | 1.40 |
| MACD | -0.65 | 0.14 |
| Stochastic Oscillator | 4.41 | 85.26 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About ZD Ziff Davis Inc.
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.